Loading clinical trials...

COMPLETEDPHASE2

Taxotere + Cisplatin in Nasopharyngeal Carcinoma

A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)

NCT00436293•Sanofi

View on ClinicalTrials.gov

Summary

Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin. Secondary objective: To assess tumor control and survival

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•International Union against Cancer stages III and IV newly diagnosed NPC

Exclusion Criteria

•Inadequate bone marrow reserve
•Inadequate renal function
•Other primary malignancy
•Evidence of distant metastases
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Hong Kong, Hong Kong

Key Dates

Start Date

December 1, 2002

Primary Completion Date

March 1, 2010

Completion Date

March 1, 2010

Last Updated

November 17, 2010

Enrollment

ACTUAL participants

Conditions

Nasopharyngeal Neoplasms

Interventions

Docetaxel

DRUG

Cisplatin

DRUG

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

NCT07326358

Nasopharyngeal NeoplasmsLaryngeal Disease

View study

ACTIVE_NOT_RECRUITINGPHASE2

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05807880

Nasopharyngeal Neoplasms

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Taxotere + Cisplatin in Nasopharyngeal Carcinoma

Inclusion Criteria

Exclusion Criteria

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

Family Study of Head and Neck Cancers in Taiwan

Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens